Showing 4981-4990 of 5621 results for "".
- VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridiahttps://modernod.com/news/veo-ophthalmics-to-support-the-masket-foundation-to-raise-awareness-of-aniridia/2477331/VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the
- Long-Term Data Show Value of Intravenous Chemotherapy in Retinoblastomahttps://modernod.com/news/long-term-data-show-value-of-intravenous-chemotherapy-in-retinoblastoma/2477326/Intravenous chemotherapy (IVC), with intra-arterial chemotherapy (IAC) or plaque radiotherapy as needed for globe salvage, can control retinoblastoma without the need for enucleation or external beam radiotherapy (EBRT), 20-year real-world outcomes show, according to a Reuters
- Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovuhttps://modernod.com/news/novartis-responds-to-asrs-note-raising-safety-concerns-of-beovu/2477325/Novartis confirmed to Eyewire News that it is launching an internal and external review of new information that raises serious safety concerns over its wet age-related macular degeneration (AMD) drug Beovu (brolucizumab). On February 23, the American Society of Retinal Specialists (ASRS) s
- Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officerhttps://modernod.com/news/eyevance-pharmaceuticals-appoints-julie-speed-as-chief-commercial-officer/2477316/Eyevance Pharmaceuticals has appointed Julie Speed to the position of Chief Commercial Officer. In her new role, Ms. Speed will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio, including Flarex (fluorometholone acetate) 0.1%, Freshk
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- HumanOptics Receives CE Mark for Trifocal Lens Triva-aAhttps://modernod.com/news/humanoptics-receives-ce-mark-for-trifocal-lens-triva-aa/2477310/HumanOptics AG has received CE marking and approval in the European market for its new trifocal lens Triva-aA. Triva-aA is the first multifocal lens from HumanOptics with three focal points. Its optimized design enables patients to enjoy good vision not only at long and near distances, but
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment
- Market Scope: Miami, Philadelphia, and Virginia Beach in Top 10 Markets of Glaucoma Treatment Opportunityhttps://modernod.com/news/market-scope-miami-philadelphia-and-virginia-beach-in-top-10-markets-of-glaucoma-treatment-opportunity/2477291/The metro areas of New York, Los Angeles, Dallas, and Chicago account for 13 percent of the US glaucoma and ocular hypertension population. However, on a per capita share basis, most of the metro areas in Florida stand out for glaucoma disease, driven largely by the state’s high median age. Naple